echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Anti-COVID-19 candidate Brilacidin has anti-SARS-CoV-2 activity! Clinical trials are imminent.

    Anti-COVID-19 candidate Brilacidin has anti-SARS-CoV-2 activity! Clinical trials are imminent.

    • Last Update: 2020-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Brilacidin is a new research drug, a polymer-based antibiotic that represents a new class of antibiotics, called host defense protein simulators or HDP analogs, that mimic non-peptide-synthetic small molecules of host defense peptides.
    HDP (also known as antimicrobial peptides) is part of the innate immune response.
    biopharmaceutical company Innovation reported today that ongoing in vitro trials support Brilacidin as a potential treatment for COVID-19.
    , chief executive of Innovation Pharmaceuticals, said: "The latest Brilacidin in-body efficacy is excellent.
    Selectivity Index (SI) is the most important indicator of the antiviral efficacy of many experimental drugs, and this new data shows that Blaclacdin has significant anti-SARS-CoV-2 activity, indicating that Brilacidin has great potential for the treatment of COVID-19".
    the vast majority of COVID-19 therapies are below Brilacidin, according to publicly available information.
    based on a recent screening of 5,632 compounds (), only 19 were identified as having anti-SARS-CoV-2 activity, with Brilacidin among them.
    Brilacidin showed strong in-body resistance to SARS-CoV-2 at low concentrations, well below the effective concentrations in Brilacidin's treatment of acute bacterial skin and skin structure infections.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.